Anaphylaxis is a documented cause of death in people of all ages, and it must be diagnosed and treated as soon as possible. The study proposes here to examine the present and new pharmacological treatment of anaphylaxis in light of new understanding in the field that can enhance quality practise and provide allergists and health workers with new tools to treat symptoms and avoid anaphylaxis. Through a greater understanding of endotypes and the use of precision medicine, the recent description of phenotypes brings fresh insight and understanding into the mechanisms and causes of anaphylaxis.

Adrenaline remains the first-line treatment for any type of anaphylaxis and is the only medicine that has been shown to avoid hospitalizations, hypoxic sequelae, and fatalities. 2-adrenergic agonists and glucagon are still used as second-line treatments for anaphylaxis, while glucocorticoids and antihistamines should only be used as a last resort. Biological medicines, such as omalizumab, have been utilised as therapeutic adjuvants in the prevention of anaphylaxis, although cost-effectiveness should be evaluated on an individual basis. Understanding the specifics of underlying mechanisms may aid in the improvement of patients’ allergological work-ups and may pave the way for the creation of prospective novel medications, such as biological agents. Expanding healthcare practitioners’ awareness of the symptoms, causes, and triggers of anaphylaxis will enhance diagnosis and management, promote patient safety, and reduce morbidity and death.